GSK Will Take Its HGS Bid Hostile; Will Shareholders Buy In?
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK plans to take its $13 per share offer straight to Human Genome Sciences shareholders after being turned down by the company last month.
You may also be interested in...
GSK And HGS Face Off Over Buyout
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.
GSK’s Bid For Human Genome Sciences: A Deal Decades In The Making
GlaxoSmithKline swoops in to acquire its research partner Human Genome Sciences – made vulnerable by the weak launch of Benlysta – for $13 per share in cash, or about $2.6 billion.
HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta
In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.